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13Objective: To examine protocol adherence to structured
intensive management in the Valsartan Intensified Primary
carE Reduction of Blood Pressure (VIPER-BP) study involving
119 primary care clinics and 1562 randomized participants.
Methods: Prospective criteria for assessing adherence to
treatment prescription, uptitration, and visit attendance at
6, 10, 14, and 18 weeks postrandomization were applied
to 1038 intervention participants. Protocol adherence
scores of 1–5 (least to most adherent) were compared to
blood pressure (BP) control during 26 weeks of follow-up.
Results: Mean age was 59.312.0 years, 963 (62%)
were men, and 1045 (67%) had longstanding
hypertension. Clinic attendance dropped from 91 (week 6)
to 83% (week 26) and pharmacological instructions were
followed for 93% (baseline) to 61% at week 14 (uptitration
failures commonly representing protocol deviations). Overall,
26-week BP levels and BP target attainment ranged from
13214/799 and 51% to 14115/83 11mmHg and
19% in those participants subject to the highest (n¼270,
26%) versus least (n¼148, 14%) per protocol adherence,
respectively; adjusted relative risk (RR) 1.22 per unit protocol
adherence score, 95% confidence interval (CI) 1.15–1.31;
for achieving BP target (P<0.001). Participants with a per
protocol score of 4 or 5 (512/1038, 49.3%) were 1.54-fold
(95% CI 1.31–1.81; P<0.001) more likely to achieve their
individual BP target compared with usual care. Clinics
equipped with a practice nurse significantly influenced
protocol adherence (adjusted RR 1.20, 95% CI 1.06–1.37;
P¼0.004) and individual BP control (RR 1.21, 95% CI
1.04–1.41; P¼0.015).
Conclusion: There is considerable potential for structured
care management to improve BP control in primary care,
especially when optimally applied.
Keywords: antihypertensive treatment, blood pressure,
cardiovascular disease, hypertension, management, primary
care, treatment targets
Abbreviations: BP, blood pressure; CI, confidence
interval; CVD, cardiovascular disease; RR, relative risk;Copyright © Lippincott Williams & Wilkins. Unaut
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INTRODUCTIONH
ypertension represents the single most important
and preventable cause of cardiovascular disease
(CVD) [1,2]. Despite evidence of reduced rates of
CVDwith progressively lower blood pressure (BP) [3] and a
broad range of antihypertensive therapies [4] to achieve
treatment targets, poorly controlled BP remains common
[5,6]. Overcoming resistance to uptitrate therapy [7] to
achieve earlier and greater BP lowering appears critical
to reducing the risk of hypertension-related CVD events. In
order to achieve this in the primary care setting in which
hypertension is predominantly managed [8], there is evi-
dence for the benefits of applying a framework, preferably
multidisciplinary [9], of increased surveillance and guided
stepped-care [10]. In addition, practice nurses are increas-
ingly becoming an important component of primaryhorized reproduction of this article is prohibited.
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Optimal blood pressure management in primary carehealthcare in Australia [11] in terms of supporting family
physicians to provide greater continuity of care for those
with chronic conditions.
The Valsartan Intensified Primary carE Reduction of
Blood Pressure (VIPER-BP) study [12], a large multicenter
trial of a structured and intensive approach to BP manage-
ment in primary care, reaffirmed the potential to achieve
better BP control in a high-risk cohort of individuals with
hypertension. The strategy was associated with an adjusted
28% increased likelihood of achieving individualized BP
control at 26 weeks. However, despite a standardized
protocol for incremental antihypertensive therapy, sup-
ported by a user-friendly, computer-based treatment algor-
ithm tool, close examination of treatment patterns from the
VIPER-BP study revealed that failure to uptitrate antihyper-
tensive therapy was still common. Given the meticulous
nature of data collected, this study provides a unique
opportunity to better understand potential barriers to
optimal BP control in primary care.
Study objective and hypothesis
We studied the extent and determinants of per protocol
adherence, from both a participant and clinician perspec-
tive, during the VIPER-BP trial. A priori and as determined
by prespecified criteria, we postulated that optimal adher-
ence to the VIPER-BP protocol would significantly improve
the primary endpoint of individualized BP control during
26-week follow-up and result in a greater decrease in BP
levels compared to baseline, both within the intervention
group and relative to usual care.
METHODS
Participants
As described in greater detail previously [13], individuals
routinely managed by family physicians partaking in the
VIPER-BP study were eligible to participate if they were
aged at least 18 years; diagnosed with hypertension requir-
ing active pharmacological treatment according to guide-
lines and; consented to participate. Exclusion criteria were
as follows: mean initial sitting SBP at least 180mmHg;
prescription of at least three antihypertensive agents; severe
renal disease (clinical diagnosis and/or estimated glomer-
ular filtration rate <60ml/min per 1.73m2); and/or contra-
indications to an angiotensin receptor blocker, calcium
channel blocker, or a thiazide diuretic.
Design
The VIPER-BP study was a multicenter randomized con-
trolled trial that recruited 2337 hypertensive individuals via
119 primary care clinics and over 250 family physicians
Australia-wide [13]. Participating clinics comprised a rep-
resentative combination of small, independent (one to two
physicians), and larger clinics with shared protocols and
governance structures (an increasing feature of primary
care in Australia). The primary endpoint reflected contem-
porary Australian guidelines [14] that recommended three
different levels of BP control, comprising a lower BP target
of 125/75mmHg or less for those with proteinuria, an
intermediate target of 130/80mmHg or less for those with
diabetes or other forms of end-organ damage, and theCopyright © Lippincott Williams & Wilkins. Unauth
Journal of Hypertensionhigher traditional target of 140/90mmHg or less for all
others. Participants were managed within the Australian
universal health insurance scheme (Medicare) that provides
reimbursed access (the majority of services without copay-
ment) to primary care clinics and subsidized pharmaco-
therapy. The study was approved by relevant ethics
committees (including the Royal Australian College of
General Practitioners) and conducted in accordance with
CONSORT guidelines for pragmatic trials [15]. Recruitment
commenced in June 2010 with final study follow-up com-
pleted in July 2011.
Procedures
Figure 1 outlines the key features of the VIPER-BP study.
Overall, 2185 consenting participants entered a standar-
dized run-in period of valsartan 80mg/day for 14–28 days
and were subject to comprehensive clinical profiling. Of
these, 416 (19%) achieved their individual BP target and
1562 were subsequently randomized (stratified according
to three BP targets) into the study.
Those randomized to the usual care group (n¼ 524)
were subject to an enhanced form of routine management
with two mandatory visits at 6 and 26 weeks for BP
comparisons. Participating physicians were asked to
manage these participants as they normally would during
26-week follow-up according to national guidelines for BP
management [14]. Notably, 367 participants (70%) in the
usual care group continued to be prescribed the run-in dose
of valsartan 80mg/day at 6 weeks despite not achieving
their individual BP target, with less than half (n¼ 228, 44%)
subsequently prescribed combination or triple therapy by
26 weeks.
Those randomized to the study intervention group
(n¼ 1038) were further randomized at a ratio of 1 : 2 to
commence valsartan monotherapy (160mg/day) or valsar-
tan combination therapy as a single pill. Once randomized
to combination therapy, physicians chose between valsar-
tan and hydrochlorothiazide or amlodipine. Supported by a
computerized treatment algorithm tool, the study protocol
called for intervention participants to be reviewed at a
series of mandatory visits at weeks 6, 10, 14, 18, and
26 postrandomization, with the instruction to uptitrate
pharmacotherapy, as shown in Fig. 1, if a participant’s
BP remained above their individual target. According to
a priori criteria, adherence to the study protocol within the
treatment arms of the study was examined according to
prescription of valsartan therapy as per group randomiz-
ation and then uptitration of therapy if a participant
remained above their individual BP target; and completion
of prescheduled study BP monitoring and follow-up visits
at weeks 6, 10, 14, and 18, with tolerance for 7-day
variance. Each visit was individually assessed on this basis
with consideration of the reason for a clinical decision not
to follow the study protocol (based on Study Investigator
notes). For example, off-protocol treatment following an
adverse event was still considered ‘per protocol’ if it was
uptitrated in response to an elevated BP. A per protocol
score of 0–5 was generated for each participant. One point
was allocated for correct treatment at randomization and an
additional point was given for each of the four visits up to
18 weeks according to correct treatment (e.g., uptitration iforized reproduction of this article is prohibited.
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National network of > 250 general practitioners screen hypertensive adults with
elevated BP according to national guidlines for individualized BP control
Primary endpoint: Proportion of randomized patients to achieve their
individualized BP target at 26 weeks
If achieve individual BP
target continue routine
care and not randomized
Valsartan 160 mg
per day
Titrate valsartan to
320 mg, then add
HCTZ and titrate, then
consider triple or
alternative therapy
Titrate valsartan to 160 mg, then titrate other component
(HCTZ to 25 mg or amlodipine to 10 mg) then consider
triple/alternative therapy
Valsartan/HCTZ
80/12.5 mg per day
Valsartan/amlodipine
80 mg/5 mg per day
Initial run-in phase
valsartan 80 mg (4 weeks)
Usual care with same BP
targets according to physician
discretion (1 in 3 patients)
VIPER intervention: vigorous computer-assisted structured care
approach including a standardized algorithm for open-label,
pharmacotherapy (2 in 3 patients)
VIPER
monotherapy
VIPER combination therapy
Stratified randomization for those
still not at individual BP target
14 day BP check, if
SBP ≥ 180 mmHg at
any point randomize
FIGURE 1 Overview of the Valsartan Intensified Primary carE Reduction of Blood Pressure (VIPER-BP) study design and treatment pathways. BP, blood pressure.
Stewart et al.clinically indicated) and a visit within the allowed time-
frame. A score of 4 or 5, allowing one deviation from the
study protocol to account for potential treatment deviation
due to an adverse event, was considered as ideal per
protocol management.
Statistical analyses
Continuous data are presented as a mean [standard devi-
ation and 95% confidence intervals (CIs), wherever appro-
priate] and categorical data as proportions. Consistent with
the primary study outcome [12], between group compari-
sons of BP control at week 26 were performed using a log
binomial generalized linear model with stratification status
at randomization as a covariate. Stratification status was fit
as a categorical variable with the three BP target groups
(125/75, 130/80, and 140/90mmHg) based on the
participant’s clinical profile. Change from baseline to
26 weeks in SBP and DBP was each subject to analysis
of covariance with treatment group and stratification status
as factors and centered baseline BP as a covariate. Study
data were also analyzed using log binomial generalized
linear models to determine the independent predictors of
protocol adherence (score of 4/5) and achievement of
the primary endpoint of individualized BP control during
26-week follow-up (n¼ 988 with an endpoint BP). In the
latter model, per protocol adherence was included as a
covariate along with a broad range of individual profilingCopyright © Lippincott Williams & Wilkins. Unaut
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istics of the primary care clinic (e.g. location, size, and
presence of a practice nurse). Where this would not con-
verge, a robust Poisson regression model was used instead.
Univariate models were first conducted, followed by a
multivariate model. Variables entered into the multivariate
analysis were those that were statistically significant
(P0.05) in the univariate analysis. Data were independ-
ently verified and analyzed by the study statistician (adverse
event) using the Stata 11 statistical package (Stata Corp.,
College Station, Texas, USA).
RESULTS
Study cohort
Of the 1562 randomized study participants, 1038 (66.5%)
were allocated to the intervention group with 360 (35%)
and 678 participants allocated to the valsartan monother-
apy and either of the combination therapy arms, respect-
ively.Groupswerewellmatched in respect to their baseline
profile (Table 1). Overall, mean age was 59.3 12.0 years,
963 (62%)weremen, and 1045 (67%) had preexisting hyper-
tension. Average BP at randomization was 149.7 16.8/
88.1 11.0mmHg, with 270 (17.3%), 843 (54.0%), and
449 (28.7%) participants, respectively, assigned a BP target
of 125/75mmHg or less, 130/80 or less, or 140/90mmHg
or less.horized reproduction of this article is prohibited.
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TABLE 1. Baseline characteristics according to group randomization
Usual care VIPER-BP intervention
All (n¼524) All (n¼1038) Monotherapy (n¼360) Combination therapy (n¼678)
Sociodemographic profile
Men 323 (62%) 640 (62%) 222 (62%) 418 (62%)
Age, years 5912 5912 5912 5912
Clinical profile
Prior hypertension 353 (67%) 692(67%) 253 (70%) 439 (65%)
Heart disease 38 (7%) 93 (9%) 35 (10%) 58 (9%)
Type 2 diabetes 106 (20%) 195 (19%) 69 (19%) 126 (19%)
Proteinuria 93 (17%) 183 (18%) 64 (18%) 119 (18%)
Microalbuminuria 127 (23%) 242 (23%) 73 (20%) 169 (25%)
BP profile and BP targets
SBP (mmHg) 14917 15017 15017 15017
DBP (mmHg) 8711 8811 8811 8911
BP target 140/90 (mmHg) 145 (28%) 304 (29%) 106 (30%) 198 (29%)
BP target 130/80 (mmHg) 286 (55%) 557 (54%) 190 (53%) 367 (54%)
BP target 125/75 (mmHg) 93 (18%) 177 (17%) 64 (18%) 113 (17%)
BP, blood pressure; VIPER-BP, the Valsartan Intensified Primary carE Reduction of Blood Pressure.
Optimal blood pressure management in primary careProtocol adherence within the intervention
group (nU1038)
Pattern of clinic visits
Table 2 shows that although the timing of actual visits
closely followed per protocol visits at days 42, 70, 98,
126 and 182, both the proportion of participants who
attended a clinic visit (range 83–91%) and the timing of
such a visit within 7 days either side of the scheduled date
(range 59–86%), steadily declined during 26-week follow-
up. Prior to the week 26 visit, participants managed by a
clinic with a practice nurse were more likely to attend a
scheduled visit (absolute difference of 2–5% for each time-
point).
Adherence to treatment uptitration schedule
Table 2 also shows the number of participants at each
scheduled clinic visit who had a BP above their individual
target. The proportion of people with uncontrolled BP
progressively fell from 76 to 60% between visits at week
6 and week 18, with a small increase in the proportion with
a SBP within 1–5mmHg (from 10.3 to 13.5% over the same
timeframe) of their target. Simultaneously, 14.3–18.2%
of participants had adverse events potentially related to
study treatment. By week 26, 49 (4.7%) were prescribedCopyright © Lippincott Williams & Wilkins. Unauth
TABLE 2. Summary of visits, clinical status, and per protocol treatme
Baseline Week 6 day 42 Week 10 d
Participants 1085 (100%) 945 (91.0%) 872 (8
Mean days of visit – 42.58.9 72.81
Visit within 7 days
of schedule
– 812/945 (86%) 678/872 (7
BP above individual
target
1085 (100%) 722 (76.4%) 625 (7
SBP within 1–5mmHg
of target
– 97 (10.3%) 110 (1
Treatment-related
adverse event recorded
– 135 (14.3%) 148 (1
Per protocol treatment
applied
962/1085 (92.7%) 701 (74.2%) 568 (6
VIPER-BP, the Valsartan Intensified Primary carE Reduction of Blood Pressure.
Journal of Hypertensionalternative pharmacotherapy. Overall, adherence to the
treatment protocol declined from 74.2% at week 6 to
65.3% at week 18.Overall per protocol adherence
A total of 54 participants (5.2%) in the intervention group
had a protocol adherence score of 0, the majority of whom
(n¼ 50) were withdrawn early from the study. A further
146 (14%) participants recorded a minimum score of 1 and
162 (16%), 164 (16%), 242 (23%), and 270 (26%) had
progressively higher adherence scores of 2, 3, 4, and 5,
respectively. Overall, 49% (512/1038) of those randomized
to the VIPER-BP intervention recorded a protocol adher-
ence score of 4 or 5.
Univariate predictors of study protocol adherence (score
of 4 or 5) were treatment modality, BP target, ethnicity of
the participant, BMI, presence of a practice nurse, and
nature of the clinic. Of these, a less stringent BP target
[BP target of 140/90 versus 125/75mmHg – relative risk
(RR) 1.36, 95% confidence interval (CI) 1.13–1.65], ethnicity
(white versus rest – RR 1.36, 95% CI 1.12–1.65), and a
practice nurse (versus rest – RR 1.23, 95% CI 1.09–1.40)
were associated with an increased likelihood of protocol
adherence. On an adjusted basis, randomization to mono-
therapy was associated with a reduced probability oforized reproduction of this article is prohibited.
nt in the VIPER-BP intervention arm (n¼1038)
ay 70 Week 14 day 98 Week 18 day 126 Week 26 day 182
4.0%) 831 (80.1%) 829 (79.9%) 857 (82.6%)
2.0 102.513.8 132.115.4 186.119.9
8%) 595/831 (72%) 586/829 (71%) 502/857 (59%)
1.7%) 536 (64.5%) 499 (60.2%) 514 (60.0%)
2.6%) 104 (12.5%) 112 (13.5%) –
7.0%) 154 (18.5%) 154 (18.2%) 141 (16.5%)
5.1%) 509 (61.3%) 541 (65.3%) –
www.jhypertension.com 1345
Stewart et al.protocol adherence (RR 0.75, 95% CI 0.65–0.87; P< 0.001).
Alternatively, the independent predictors of protocol
adherence were the patient’s ethnicity (white being the
predominant group versus rest – RR 1.36, 95% CI 1.13–1.65;
P¼ 0.004) and the practice nurse attended clinics (RR 1.20,
95% CI 1.06–1.37; P¼ 0.004).
Impact of protocol adherence on blood pressure
control
Figure 2 summarizes the BP measurements recorded at the
structured clinic visits as part of the study interventionCopyright © Lippincott Williams & Wilkins. Unaut
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FIGURE 2 Pattern of blood pressure (BP) levels according to per protocol treatment (a
and P<0.001. All three figures show the impact of events/decisions occurring at a pr
(e.g., visit 2 at week 10).
1346 www.jhypertension.comaccording to three key parameters observed at the preced-
ing visit (e.g. lack of uptitration of treatment at week
6 impacting on the BP recorded at week 10). These were
adherence to the treatment prescription and uptitration
protocol; whether the participant achieved their BP target;
and whether the participant had an adverse event poten-
tially related to study treatment. We observed a widening
and positive impact on BP control as the 26-week follow-up
period progressed in response to per protocol treatment
during the preceding visit. Those who achieved their BP
goal at the preceding visit were more likely to once againhorized reproduction of this article is prohibited.
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* * ***
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), achievement of BP target (b), and any adverse events (c). P<0.05, P<0.01,
eceding visit (e.g., visit 1 at week 6) on BP levels recorded at the next study visit
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Optimal blood pressure management in primary careachieve this goal at the next visit. Alternatively, a prior
adverse event was associated with a higher BP at the
subsequent visit, although no difference was observed
on this basis at week 26.
Figure 3 shows the relationship between per protocol
adherence and BP control in those who completed 26-week
follow-up (n¼ 857).
Figure 4 [16–18] plots the baseline predictors of the
primary endpoint (individual BP control) for participants
in the VIPER-BP intervention groupwith available endpoint
BP data (n¼ 988). Men were one third more likely to
achieve their individual BP target compared with women
(adjusted RR 1.31, 95% CI 1.13–1.53; P< 0.001) and those
with a higher BMI less likely (RR 0.97, 95% CI 0.96–0.98 per
kg/m2; P< 0.001). The less stringent the BP target (RR 2.02,
95% CI 1.38– 2.95 and 3.36, 95% CI 2.31–4.89 for a BP target
of 130/80 and 140/90mmHg, respectively, versus 125/
75mmHg), the more likely this was achieved. Those attend-
ing a clinic staffedwith a practice nursewere alsomore likely
to achieve the primary endpoint (RR 1.21, 95% CI 1.04–1.41;
P¼ 0.015). Alternatively, attendance at a clinic part of a larger
network was a negative predictor for achieving BP target
(ranging from 26.5 to 36.5% in these clinics versus 50.4% for
the rest). Increasing per protocol adherence was a strong
predictor of achieving individual BP control (RR 1.22, 95%CI
1.15–1.31; P< 0.001 per unit protocol score).Comparison of per protocol treatment versus
usual care
In comparison to usual care, intervention participants
managed as per study protocol were 1.5-fold more likely
to achieve their individual BP target [RR 1.54, 95% CI 1.31–
1.81; 138/504 (27.4%) versus 245/512 (47.8%), P< 0.001].Copyright © Lippincott Williams & Wilkins. Unauth
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Journal of HypertensionThey were also 1.3-fold more likely to achieve a BP of less
than 140/90mmHg [RR 1.33, 95% CI 1.21–1.47; 272/504
(54.0%) versus 363/512 (70.9%), P< 0.001]. Consequently,
compared with usual care, the numbers needed to treat in
the intervention group to achieve this BP target was
5.9 (95% CI 4.4–9.1). Mean change in BP from baseline to
26 weeks was markedly higher in the per protocol treatment
group (15.6 16.1/8.9 9.4mmHg) compared with the
usual care group (10.2 17.5 /5.2 10.2mmHg); the
adjusted mean differences in BP in favor of the VIPER-BP
group being5.8 (95% CI 7.4 to4.1)/3.5 (95% CI4.6
to 2.5)mmHg (P< 0.001 for both comparisons).
DISCUSSION
Although there is strong evidence to support the appli-
cation of structured programs in primary care to optimize
BP management [10], there is a paucity of detail to describe
how they best work and can be effectively applied. Using
comprehensive data from a large multicenter randomized
controlled trial of intensive BP management [12], we pro-
spectively examined the predictors and consequences of
greater adherence to the study protocol on subsequent BP
control. As expected [7], we found some resistance to
uptitrating antihypertensive therapy when clinically indi-
cated, but not typically when participants were close to
their BP target. As also expected [19], although adverse
events appeared to initially influence prescribing patterns
and BP control, they did not unduly affect BP goal attain-
ment at 6 months. Ultimately, it was the level of BP control
being sought and level of adherence to the study protocol
that most influenced individual BP control. Compared with
those who were least managed according to the study
protocol, participants in the intervention group subject toorized reproduction of this article is prohibited.
47)
erence score
4 (n = 230) 5 (n = 266)
82.3 ± 10.5 mmHg
UC (n = 504)
139.1 ± 15.0 mmHg
UC (n = 504)
ks (n¼857). Blue dashed arrows indicate the mean endpoint blood pressure (BP;
confidence interval, CI) differences in SBP and DBP relative to a per protocol
(P<0.05) or more (4 or 5; P<0.001). Standard error bars are contained within
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Age (per year)
Male vs. female
Married vs. rest
Employed vs. rest
< 12 years education vs. rest
Mono vs. combination therapy
Randomized systolic BP (per mmHg)
Randomized diastolic BP (per mmHg)
Absolute CV risk score (per unit)
Current smoker vs. rest
Depressive symptoms vs. rest
Metropolitan clinic vs. rest
Network clinic vs. rest
0.00 1.00 2.00
Adjusted relative risk of achieving individual BP target
3.00 4.00 5.00 6.00
Clinic with a practice nurse vs. rest
Per protocol adherence score (per unit score 1–5)
BMI (per kg/m2)
Caucasian vs. rest
BP target 130/80 vs. 125/75
BP target 140/90 vs. 125/75
FIGURE 4 Predictors of individual blood pressure (BP) control in the intervention arm (n¼988). Monotherapy versus combination therapy is based on intention-to-treat
randomization. Absolute cardiovascular risk is based on Framingham criteria [16,17] for 5-year risk of a cardiovascular event. BMI was calculated by standardized
anthropometric profiling. Depressive symptoms were defined as a positive response to the two-item Arroll screening tool [18]. CV, cardiovascular.
Stewart et al.optimal protocol adherence recorded a 26-week BP that
was around 9/5mmHg less. Moreover, they were two-fold
more likely to attain their individual BP target (even if at the
lower target of 125/75mmHg).
Significantly, the presence of a practice nurse independ-
ently predicted the successful application of the study
intervention (including timing and attendance at clinic visits
and likelihood of treatment uptitration) and subsequent
attainment of BP control. In Australia, as in many other
healthcare systems, practice nurses typically assume a com-
bination of clinical and administrative duties [20]. Despite
data supporting a more proactive role for practice nurses to
optimize BP management [9], this represents an under-
developed component of primary care, particularly when
considering the evidence in favor of other nurse-coordi-
nated models of care in chronic disease [21,22]. Successful,
algorithm-based interventions [9,10] to improve BP man-
agement have increased potential if there is someone like a
practice nurse to implement them. Our observations that
larger clinics with shared protocols/governance were less
likely to achieve individualized BP control reinforce the
need to maintain high standards of care across larger
organizations with typically higher volume caseloads per
physician [20].
At the individual level, three factors independently influ-
enced successful BP control. First, menwere approximately
one-third more likely than women to achieve the primary
endpoint. Although this finding appears to contrast with
earlier study findings [23], it probably reflects the random-
ization of female participants with more persistent forms of
hypertension and well described, sex-based differences in
treatment response [24]. Reinforcing the links between a
high population prevalence of both obesity and hyperten-
sion [25], increasing BMIwas also negatively correlated with
BP response to treatment. It is known that more obese
individuals have increased sympathetic drive [26] that
would not necessarily respond to the antihypertensive
agents used in this study. We also found that participantsCopyright © Lippincott Williams & Wilkins. Unaut
1348 www.jhypertension.comwith depressive symptoms were also less likely to attain
their individual BP target. Given that this condition is also
not uncommon in hypertensive individuals, these data
reinforce the need to proactively routinely screen for
depression in order to optimize adherence and treatment
response to antihypertensive therapy. Overall, these data
reinforce the therapeutic benefits of individualizing treat-
ment pathways within a structured care approach.
There are a number of limitations that influence
interpretation of these data and their applicability to other
healthcare systems and wider clinical practice. As originally
described [12], study physicians are likely to represent those
most interested in hypertension management and they
recruited participants by invitation. The application of
the study protocol was facilitated by the Australian health-
care system with health subsidies and copayments for
participants. As highlighted by potential variances in the
size and nature of practices, there is a degree of hetero-
geneity in Australian primary care that is difficult to describe
and control for; this is one of the reasons for not applying a
cluster design. It is also possible that lower socioeconomic
or some ethnic groups may be underrepresented in the
study cohort. Similar results from an equivalent trial under-
taken in Canada [27] and a systematic review of the overall
impact of structured BPmanagement programs [10] support
the validity of our findings beyond Australia. Finally, given
the significant findings in relation to practice nurses, it is
important to note we did not document their specific role
in study management and their precise impact remains
unknown.
In summary, one in three participants randomized to the
VIPER-BP intervention was exposed to the optimal level of
protocol adherence and this was associated with markedly
better BP control. Predictors of greater per protocol
adherence and achievement of individualized BP control
depended on a range of clinical, treatment, practice, and
individual patient factors. These data reinforce the potential
to better tailor management to individual needs in order tohorized reproduction of this article is prohibited.
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Optimal blood pressure management in primary careoptimize BP management in primary care. A potentially key
role for practice nurses was identified in this regard and
further research is required to best translate the evidence
from trials such as this into clinical practice.
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Stewart et al.Reviewers’ Summary Evaluations
Reviewer 1
Modern antihypertensive agents are designed to reduce
blood pressure. Unfortunately, for reasons depending on
the patients and/or the treating physicians these drugs are
often not used optimally or not at all. Better adherence to a
vigorous treatment protocol must be expected to improve
blood pressure control of hypertensive patients, and this is
exactly what the authors report. Any other finding would
have been difficult to accept. The structured approach of
the investigation and the number of patients enrolled gives
this observation some weight.
Reviewer 2
The aim of the study was to analyze the determinants of
per protocol adherence and to compare usual care andCopyright © Lippincott Williams & Wilkins. Unaut
1350 www.jhypertension.comVIPER-BP intervention in achieving BP control. The study
looked at the proportion of hypertensive patients achiev-
ing three different levels of BP control ( 125/75mmHg
for proteinuric patients; < 130/80mmHg for patients with
diabetes or/and organ damage; and < 140/90mmHg for
all other patients) reflecting the current Australian guide-
lines, which are different from the 2013 ESH/ESC guide-
lines.
A specific per protocol score was generated for each
participant to assess adherence and treatment. A score of
4–5 (allowing one deviation from the study protocol)
was considered ideal per protocol management, and was
more likely to achieve individual BP targets compared
with usual care. The study identified a potentially key
role for practice nurses to be translated into clinical
practice.horized reproduction of this article is prohibited.
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